Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
| Autor: | Antonieta Salud, Manuel Valladares-Ayerbes, Javier Sastre, Elena Asensio, Luis Robles, Eduardo Díaz-Rubio, Fernando Rivera, Enrique Aranda, Albert Abad, Auxiliadora Gómez-España, Vicente Alonso-Orduña, Alfredo Carrato, Clara Montagut, Maria Jose Safont, Cristina García González, Manuel Benavides, Encarnación González-Flores, Pilar García-Alfonso, Jose María Vieitez |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Oncology
medicine.medical_specialty Rectal Neoplasms Colorectal cancer business.industry Tumor resection Antibodies Monoclonal Angiogenesis Inhibitors General Medicine medicine.disease Pooled analysis Internal medicine Antineoplastic Combined Chemotherapy Protocols Colonic Neoplasms medicine Humans Cooperative group Surgery Colorectal Neoplasms business Retrospective Studies |
| Zdroj: | European Journal of Surgical Oncology. 48:1123-1132 |
| ISSN: | 0748-7983 |
| Popis: | Retrospective studies and meta-analyses suggest that upfront primary tumour resection (UPTR) confers a survival benefit in patients with asymptomatic unresectable metastatic colorectal cancer (mCRC) undergoing chemotherapy, however a consensus of its role in routine clinical practice in the current era of targeted therapies is lacking. This retrospective study aimed to analyse the survival benefit of UPTR in terms of tumour location and mutational status, in patients with synchronous mCRC receiving chemotherapy and targeted therapy.Survival was analysed in a pooled cohort of synchronous mCRC patients treated with a first-line anti-VEGF or anti-EGFR inhibitor in seven trials of the Spanish TTD group, according to UPTR, tumour-sidedness and mutational profiling.Of 1334 eligible patients, 642 (48%) had undergone UPTR. UPTR was associated with significantly longer overall survival (OS; 25.0 vs 20.3 months; HR 1.30, 95%CI 1.15-1.48; p 0.0001). UPTR was associated with significant OS benefit in both left-sided (HR 1.38, 95%CI 1.13-1.69; p = 0.002) and right-sided (HR 1.39, 95%CI 1.00-1.94; p = 0.049) tumours, RASwt (HR 1.29, 95%CI 1.05-1.60; p = 0.016) and BRAFwt (HR 1.49, 95%CI 1.21-1.84; p = 0.0002) tumours, and treatment with anti-EGFRs (HR 1.47, 95%CI 1.13-1.92; p = 0.004) and anti-VEGFs (HR 1.25, 95%CI 1.08-1.44; p = 0.003). Multivariate analysis identified number of metastatic sites, RAS status, primary tumour location and UPTR as independent prognostic factors for OS.Considering the selection bias inherent to this study, our results support UPTR before first-line anti-EGFR or anti-VEGF targeted therapy in right and left-sided asymptomatic unresectable synchronous mCRC patients. RAS/BRAF mutational status may also influence UPTR function. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect